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SHORT COMMUNICATION
O'-methylguanine-DNA methyltransferase activities in biopsies of human
melanoma tumours
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S_y Tumour samples obtained from one primary meanoma and several lymph node and skin meta-
stases wme analysed for O e- ann A methyltaneras (MGMT) activity. While lymph node and
skin had similar aver MGMT activity, the variane was nty higber in lymph node
metastases Variability m MGMT actity was frequntly observed i diffrent metastases m the same
individual and to a ksser extent within meastases
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Chemotherapy of dis inated malignant melanoma is often
unsuccessful since melanoma tumours frequently show intrn-
sic drug resitance or acqulire istance to drugs during
chemotherapy (Houghton et al., 1992). The monofunctional
alkylating agent 5-(3',3'-dimethyl-l-triazno)imidazole-4-
caboxamide (DTIC) is the drug which has been most ex-
sively used in chemotheapy of metastatic melanoma (Comis,
1976). Treatment with DTIC as a single agent results in a
20% objective rission rate in metastatic melanoma, while a
35-40% objective remission rate has been achieved when
DTIC is given in combination with other drugs (Houghton et
al., 1992). Unfortunately, however, the majority of patients
only obtain partial remissions and the average duration of
remission is usually only a few months (Ringborg et al.,
1989, 1990).
DTIC is demethylated by liver microsomes to the active
methylating metabolite 5-(3'-methyl-1-triazeno)-fimidazole
carboxamide (MTIC), which is further decomposed to a
methyl-diazonium ion that reacts with both the O'- and
N7-atoms of guanine residues in DNA (Meer et al., 1986).
Methylation of the 06-atom of guanine is considered to be
the most cytotoxic adduct (Pegg, 1990).
Methyl and other short alkyl groups bound to the O6-atom
of guanine are removed by a unique repair protein, 06-
methylguanine-DNA methyltransferase (MGMT), which is
present in both prokaryotic and eukaryotic cells (Pegg, 1990).
At removal, the adducts are transferred to a cysteine moiety
within the MGMT protein, which is thereby irreversibly
inactivated. De novo synthesis of the protein is required for a
continuous repair function.
Human MGMT is a 22 kDa protein which appears to be
present in varying amounts in all normal human tiss. The
content of MGMT also varies between individuals (Myrnes
et al., 1983). In contrast to normal cells, approximately 20%
of cell lines derived from human tumours lack MGMT
activity (mex- or mer- cells) (Day et al., 1980a, b; Skrlar and
Strauss, 1981; Yarosh et al., 1983). Such mex- cells are
hypersensitive to methylating agents (Day et al., 1980a, b;
Sklar and Strauss, 1981; Yarosh et al., 1983; Scudiero et al.,
1984) and chloroethylnitrosoureas (Erickson et al., 1980a, b;
Scudiero et al., 1984). Although a proportion of tumour cell
lines are mex-, it has not been extensively investigated
whether any tumours in patients consist of mex- cells. If
such mex- tumours exist, they could be those that respond to
clinical chemotherapy with drugs suh as DTIC, while
tumours exhibiting the mex+ phenotype might be drug resis-
tant. Existing data on MGMT activity in extracts from fresh
human tumour biopsies indiate that low lewls of MGMT
are sometimes observed, although this phenomenon may be
leks common than in established tumour cell lines (Myrnes et
al., 1984; Wiestler et al., 1984; Frosina et al., 1990; Cao et
al., 1991; Citron et al., 1991; Mineura et al., 1994).
In the present study the MGMT activities in biopsies of
human melanoma tumours are presented. The aim was to
compare the MGMT activities in tumours in different indivi-
duals as well as to invesgate the variability between different
metastases in the same person. In several cases we also
measured MGMT activity in separate parts of the same
tumour, to detrmine if the activity is heterogenous within
the tumour.
MAt and ehds
Patients
A total of 46 melanoma tumour samples were collected from
34 subjects followed at the Department of Oncology,
Radiumhmmet, Karolinska Hospital. In most cases biopsies
were obtained during surgery for lymph node or skin meta-
stases, but in one patient a sample from the primary
melanoma was also obtained.
Preparation oftwnour extracts
Normal tissue surrounding the tumour was excised and the
tumours were divided into small pieces, frozen in liquid
nitrogen and stored at -70-C until assayed. Cell extracts
were preared by homogenising an approximately 0.1 cm3
piece of the tumour in a microdismembrator H (B. Braun,
Melsungen, Germany) for 30s. The dry powder was sus-
pended an equal volume of lysis buffer containing 300 mM
potasum chlonde, 50mm Tris-HCI (pH 7.5), 10mm
dithiothreitol, 1 mM EDTA and 0.5 mM phenylmethylsul-
phonyl fluoride and left on ice for 30 min. Debris was
removed by centrifugation for 30min at 13,000 r.p.m. at 4C
(Ferguson et al., 1988). The protein concentration of extracts
was determined by the Bradford (1976) method (Bio-Rad)
using bovine serum albumin as standard.
MGMT assay
The MGMT activities of the cell extracts were measured as
previously described (Egyhizi et al., 1991) by removal of
[3Hmethyl groups from the O'-position of Micrococcus hlteur
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DNA alkylated with [3HJmethylnitrosourea (MNU, specific
acitivity 18-29Cimmol-', Amersham) and treated by heat
to remove N-alkylated purines (Karran et al., 1979).
Thymidine kuise (TK) assa)
The TK activities of cell extracts were measured by their
ability to phosphorylate thymidine, and calculated as
picomoles of thymidine phosphorylated per 10 min per
microgram of extract protein (Karran et al., 1977).
In only two of ten metastases a more than 2-fold difference
was observed in different parts of the tumour.
The MGMT expression in some cultured cell lines has
been shown to be co-regulated with the expression of two
unrelated enzymes, galactokinase and thymidine kinase (TK)
(Karran et al., 1990). The mechanisms causing this pheno-
menon are unknown. To find out if co-regulation also occurs
in vivo, we analysed TK activities in several extracts, but
found no correlation between the MGMT and TK activities
in melanoma metastases (r = 0.26).
Results
MGMT activities were examined in extracts made from sur-
gical biopsies of two different kinds of melanoma metastases:
20 skin and 25 lymph node. A biopsy from a primary tumour
was also obtained. At the time of biopsy none of the patients
had received chemotherapy. The quality of extracts made
from tumour biopsies was examined by SDS-polyacrylamide
gel electrophoresis and by measurements of an independent
enzyme hypoxanthine-guanine phosphoribosyl transferase
(HGPRT). Extracts showed no large variations using these
two parameters (data not shown).
There was a considerable variation in MGMT activity
among the tumours (Figure 1). Only lymph node metastases
showed MGMT activities above 0.6 pmol mg-' protein, but
the average MGMT activities in skin (0.21 ± 0.11 pmol mg-'
protein, mean ± s.d.) and lymph node metastases (0.27 ±
0.22 pmol mg-1 protein) were similar. The variance, however,
was significantly higher (P<0.01) in lymph node than in skin
metastases.
It is possible to study how the MGMT activity differs
between separate metastases in -he same individual, since
biopsies from two or more metastases were available from
seven of the patients (Figure 2). In three of the seven subjects
the difference in MGMT activity between metastases was
more than 2-fold.
Lee et al. (1992) have shown that the levels of MGMT
protein analysed with polyclonal antibodies varies within
melanoma metastases, and that only some of the cells in the
tumours express the MGMT protein. We also analysed the
MGMT activities in different parts of individual metastases
(Figure 3). A heterogeneity in MGMT activity within indivi-
dual metastases was registered but the variation was not as
pronounced as that between different metastases (Figure 3).
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Approximately 20% of tumour cell lines exhibit the mex-
phenotype (Day et al., 1980a, b; Sklar and Strauss. 1981;
Yarosh et al., 1983). It is of importance to find out if this is
an in vitro artifact, or if it reflects the situation in the
tumours of patients in vivo. We therefore examined the
MGMT activity in biopsies of melanoma metastases, and
observed that low levels of MGMT activity (mex-; MGMT
activity <0.05 pmol mg-' protein) were rarer in these meta-
stases than in tumour cell lines. The explanation for this
could be that during establishment of tumour cell lines mex-
cells might have a growth advantage.
Our results show similar mean MGMT activities in lymph
node and skin metastases (Figure 1). Interestingly, the
variance among the lymph node metastases was significantly
higher than among the skin metastases. In evaluating these
results we must take into consideration the fact that the
tumours contain normal stroma and blood cells in addition
to tumour cells. The results represent the average MGMT
activity of all cells in the biopsy, not just tumour cells. It is
thus possible that detectable MGMT activities of some
tumours depend on non-tumour cells while the melanoma
cells may be mex-.
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Fgwe 2 MGMT activities in seven patients from whom two or
more samples were obtained (0, lymph node metastases; *, skin
metastases; A, primary tumour).
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Figie 1 The distribution of MGMT activities in crude cell
extracts from 25 lymph node (0) and 20 skin metastases
(-).
Fiugre 3 MGMT activities in extracts from two separate parts
of the same tumour in ten metastases (symbols as in Figure
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Heterogeneity in MGMT activity between different meta-
stases in a patient seems to be relatively frequent. This result
is consistent with the possibility that primary tumours may
contain several subpopulations of tumour cells with meta-
static properties which differ in MGMT activity. The meta-
static process could then result in the dominance of different
tumour cell populations in different metastases. Alternatively,
the cells in the primary tumour may have a uniform activity
of MGMT. and this original cell population could also be
present in some of the metastases, while in other metastases
subpopulations of cells with different MGMT activities may
arise during tumour progression. If such cells have a growth
advantage over the original cell population they could
become the dominating cells in the metastasis.
In the present study we have found a wide- vanration in
MGMT activity between melanoma metastases. We now plan
to investigate whether MGMT activity is of importance for
resistance to clinical chemotherapy containing DTIC in
malignant melanoma.
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